Sanofi has reported positive data from the Phase III IKEMA clinical trial of Sarclisa (isatuximab) in combination with carfilzomib and dexamethasone to treat patients with relapsed multiple myeloma.

When compared to carfilzomib and dexamethasone alone, Sarclisa combination met the trial’s primary endpoint with significantly improved progression-free survival at first planned interim analysis.

Results also showed no new safety signals with the combination therapy.

Sanofi research and development global head John Reed said: When Sarclisa was added to standard-of-care treatment carfilzomib and dexamethasone in this Phase III trial, results clearly demonstrated a significant reduction in risk of disease progression or death.

“This is the second positive Phase III trial for Sarclisa, further supporting the potential our medicine has to improve outcomes for patients struggling with relapsed multiple myeloma.”

Sanofi’s drug is a monoclonal antibody designed to attach to a specific epitope on the CD38 receptor found on multiple myeloma cells. It works via various mechanisms of action, including apoptosis and immunomodulatory activity.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

In the US, the drug in combination with pomalidomide and dexamethasone is approved to treat relapsed refractory multiple myeloma in adults who have had at least two prior therapies.

The randomised, multi-centre, open label IKEMA trial assessed the drug in a total of 302 relapsed multiple myeloma patients at 69 centres across 16 countries.

Participants received intravenous Sarclisa at a 10mg/kg dose once weekly for four weeks, followed by every other week for 28-day cycles. The drug was given with 20mg/56mg/m² carfilzomib twice weekly and dexamethasone at the standard dose.

In addition to the primary endpoint, the trial assessed secondary endpoints, such as overall response rate, minimal residual disease, complete response rate, overall survival, and safety.

Sarclisa is undergoing additional Phase III trials in combination with current standard to treat multiple myeloma. It is also being studied in other blood cancers and solid tumours.